Aethlon Medical INC 8-K filings

Aethlon Medical announced a 24% reduction in operating expenses for the fiscal first quarter ended June 30, 2024, and provided updates on its Hemopurifier clinical trials.

Aethlon Medical has secured a second ethics committee approval to proceed with a clinical trial of its Hemopurifier device in cancer patients at Pindara Private Hospital in Australia.

Aethlon Medical, Inc. has dismissed Baker Tilly US, LLP and engaged Haskell & White LLP as its new independent registered public accounting firm, effective July 1, 2024.

Aethlon Medical announced its fiscal year 2024 financial results and provided an update on the progress of its Hemopurifier device, including ethics approval for a cancer trial in Australia.

Aethlon Medical, Inc. reports 9,229,725 outstanding shares following a recent best-efforts public offering.

Aethlon Medical has announced the pricing of a public offering to raise approximately $4.7 million through the sale of common stock, pre-funded warrants, and accompanying Class A and Class B warrants.

Aethlon Medical reports successful in vitro binding study results showing its Hemopurifier device can remove extracellular vesicles from cancer patient plasma, supporting planned Phase 1 clinical trials.

Aethlon Medical's corporate presentation details the potential of its Hemopurifier device in treating cancer, viral infections, and improving organ transplantation outcomes.

Aethlon Medical announced its fiscal third quarter results, highlighting progress in its Hemopurifier development and clinical trials, while also reporting increased operating expenses and net loss.